Lake Street analyst Frank Takkinen raised the firm’s price target on Beta Bionics (BBNX) to $35 from $30 and keeps a Buy rating on the shares after the company reported top and bottom line upside in Q3 and raised guidance. A war chest of $274M of cash at Q3 end supports “aggressive investment,” adds the analyst, who thinks shares deserve a premium valuation.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBNX:
- Beta Bionics price target raised to $31 from $26 at Stifel
- Beta Bionics price target raised to $33 from $26 at Goldman Sachs
- Beta Bionics price target raised to $23 from $17 at Baird
- Beta Bionics price target raised to $32 from $26 at Piper Sandler
- Beta Bionics Reports Strong Q3 Growth and Raises Guidance